Volkow Nora D, Wang Gene-Jack, Kollins Scott H, Wigal Tim L, Newcorn Jeffrey H, Telang Frank, Fowler Joanna S, Zhu Wei, Logan Jean, Ma Yeming, Pradhan Kith, Wong Christopher, Swanson James M
National Institute on Drug Abuse, 6001 Executive Blvd, Room 5274, MSC 9581, Bethesda, MD 20892, USA.
JAMA. 2009 Sep 9;302(10):1084-91. doi: 10.1001/jama.2009.1308.
Attention-deficit/hyperactivity disorder (ADHD)--characterized by symptoms of inattention and hyperactivity-impulsivity--is the most prevalent childhood psychiatric disorder that frequently persists into adulthood, and there is increasing evidence of reward-motivation deficits in this disorder.
To evaluate biological bases that might underlie a reward/motivation deficit by imaging key components of the brain dopamine reward pathway (mesoaccumbens).
DESIGN, SETTING, AND PARTICIPANTS: We used positron emission tomography to measure dopamine synaptic markers (transporters and D(2)/D(3) receptors) in 53 nonmedicated adults with ADHD and 44 healthy controls between 2001-2009 at Brookhaven National Laboratory.
We measured specific binding of positron emission tomographic radioligands for dopamine transporters (DAT) using [(11)C]cocaine and for D(2)/D(3) receptors using [(11)C]raclopride, quantified as binding potential (distribution volume ratio -1).
For both ligands, statistical parametric mapping showed that specific binding was lower in ADHD than in controls (threshold for significance set at P < .005) in regions of the dopamine reward pathway in the left side of the brain. Region-of-interest analyses corroborated these findings. The mean (95% confidence interval [CI] of mean difference) for DAT in the nucleus accumbens for controls was 0.71 vs 0.63 for those with ADHD (95% CI, 0.03-0.13, P = .004) and in the midbrain for controls was 0.16 vs 0.09 for those with ADHD (95% CI, 0.03-0.12; P < or = .001); for D(2)/D(3) receptors, the mean accumbens for controls was 2.85 vs 2.68 for those with ADHD (95% CI, 0.06-0.30, P = .004); and in the midbrain, it was for controls 0.28 vs 0.18 for those with ADHD (95% CI, 0.02-0.17, P = .01). The analysis also corroborated differences in the left caudate: the mean DAT for controls was 0.66 vs 0.53 for those with ADHD (95% CI, 0.04-0.22; P = .003) and the mean D(2)/D(3) for controls was 2.80 vs 2.47 for those with ADHD (95% CI, 0.10-0.56; P = .005) and differences in D(2)/D(3) in the hypothalamic region, with controls having a mean of 0.12 vs 0.05 for those with ADHD (95% CI, 0.02-0.12; P = .004). Ratings of attention correlated with D(2)/D(3) in the accumbens (r = 0.35; 95% CI, 0.15-0.52; P = .001), midbrain (r = 0.35; 95% CI, 0.14-0.52; P = .001), caudate (r = 0.32; 95% CI, 0.11-0.50; P = .003), and hypothalamic (r = 0.31; CI, 0.10-0.49; P = .003) regions and with DAT in the midbrain (r = 0.37; 95% CI, 0.16-0.53; P < or = .001).
A reduction in dopamine synaptic markers associated with symptoms of inattention was shown in the dopamine reward pathway of participants with ADHD.
注意力缺陷多动障碍(ADHD)——以注意力不集中和多动冲动症状为特征——是最常见的儿童精神障碍,且常持续至成年,越来越多的证据表明该障碍存在奖励动机缺陷。
通过对大脑多巴胺奖励通路(中伏隔核)的关键组成部分进行成像,评估可能构成奖励/动机缺陷基础的生物学因素。
设计、地点和参与者:2001年至2009年期间,我们在美国布鲁克海文国家实验室,使用正电子发射断层扫描技术测量了53名未服药的ADHD成年患者和44名健康对照者的多巴胺突触标记物(转运体和D(2)/D(3)受体)。
我们使用[(11)C]可卡因测量多巴胺转运体(DAT)的正电子发射断层扫描放射性配体的特异性结合,使用[(11)C]雷氯必利测量D(2)/D(3)受体的特异性结合,以结合潜能(分布体积比率-1)进行量化。
对于两种配体,统计参数映射显示,在大脑左侧多巴胺奖励通路区域,ADHD患者的特异性结合低于对照组(显著性阈值设定为P <.005)。感兴趣区域分析证实了这些发现。伏隔核中对照组DAT的平均值(平均差异的95%置信区间[CI])为0.71,ADHD患者为0.63(95%CI,0.03 - 0.13,P =.004);中脑中对照组为0.16,ADHD患者为0.09(95%CI,0.03 - 0.12;P ≤.001);对于D(2)/D(3)受体,伏隔核中对照组的平均值为2.85,ADHD患者为2.68(95%CI,0.06 - 0.30,P =.004);中脑中,对照组为0.28,ADHD患者为0.18(95%CI,0.02 - 0.17,P =.01)。分析还证实了左侧尾状核的差异:对照组尾状核DAT的平均值为0.66,ADHD患者为0.53(95%CI,0.04 - 0.22;P =.003),对照组尾状核D(2)/D(3)的平均值为2.80,ADHD患者为2.47(95%CI,0.10 - 0.56;P =.005),以及下丘脑区域D(2)/D(3)的差异,对照组的平均值为0.12,ADHD患者为0.05(95%CI,0.02 - 0.12;P =.004)。注意力评分与伏隔核(r = 0.35;95%CI,0.15 - 0.52;P =.001)、中脑(r = 0.35;95%CI,0.14 - 0.52;P =.001)、尾状核(r = 0.32;95%CI,0.11 - 0.50;P =.003)和下丘脑(r = 0.31;CI,0.10 - 0.49;P =.003)区域的D(2)/D(3)以及中脑的DAT(r = 0.37;95%CI,0.16 - 0.53;P ≤.001)相关。
ADHD参与者的多巴胺奖励通路中,与注意力不集中症状相关的多巴胺突触标记物减少。